Chest
-
Respiratory Support PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Non invasive ventilation (NIV) in COPD patients with acute respiratory failure (ARF) is a clearly effective treatment. The long-term prognosis of COPD patients who required NIV during the hospital admission is not known exactly. ⋯ The following authors have nothing to disclose: Andrés Vega Arias, Jesús Sánchez, Virginia Almadana, Maria Pavon, Patricia Guerrero, Natalia Fouz, Ana Gómez-Bastero, Juan Polo, Teodoro MontemayorNo Product/Research Disclosure Information.
-
Lung Cancer Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Lung cancer remains the leading cause of cancer deaths wordlwide. There is a limited data evaluating overall five years lung cancer survival. The aim of this study is to describe the characteristics of our patients with lung cancer and the five years survival rate in our hospital. ⋯ The following authors have nothing to disclose: Rosa Maria Ortiz Comino, Noemi Burgos Guadix, Rosa Lina De los Santos de Lopez, Ana Dolores Romero Ortiz, Manuel De VegaNo Product/Research Disclosure Information.
-
Respiratory Support PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To evaluate outcome of weaning failure patients sent home on invasive home mechanical ventilation.(IHMV)METHODS: Overall feasibility,safety,efficacy and cost-effectiveness of 10(n=10) tracheostomised patients unable to wean discharged from Metro Centre for Respiratory Disease on IHMV in the year 2012, were analyzed .Cost-effectiveness was evaluated in terms of cost saved per patient discharged alive, life year saved and cost per year of life saved. The survival was calculated by the 30 days mortality rate. Efficacy was calculated by number of decannulation and discontinuation of IMV. Data was statistically analyzed using χ2 test with level of significance taken at p ≤ 0.05RESULTS: The mean age of the patient population was 72.1±12.84years.Mean duration of hospitalization was 23.7±12.62 days whereas ICU stay was 11.7±6.01 days. Six patients were sent home on BiPAP (S/T mode) with IPAP of 14.4 ± 1.63 cm H2O and EPAP of 6.11 ± 0.8 cm H2O, whereas 3 patients were sent home on BIPAP with AVAPS and one on SIMV(PC mode).Median days patients were followed up at home were 35.8 days with a median duration of usage of MV being 18.6 days. The 30 days mortality was 40% (p=0.188).Two patients required readmission.The cost saved per patient discharged alive, who either died or were readmitted was US$ 16241.72. The life year saved was 0.13(p= 0.361) whereas the cost-per year of life saved was US$ 151662.18. Three(n= 3)patients (30.0%; p= 0.241) were successfully decannulated and continue on IHMV beyond 30 days, two discontinued HMV. ⋯ The following authors have nothing to disclose: Mir Ali, Deepak TalwarNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Combined use of long-acting bronchodilators with different mechanism of action optimizes bronchodilation and may reduce the risk of exacerbations. QVA149 is a novel dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237) for the maintenance treatment of COPD. Here, we report findings from the SPARK and ILLUMINATE studies of the IGNITE program, with a focus on the rate and prevention of exacerbations. ⋯ Donald Banerji: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis EmployeeClinical trial results of QVA149, combination of approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
SleepSESSION TYPE: Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 10:45 AM - 11:45 AMPURPOSE: To evaluate sleep quality using polysomnographic parameters and validated questionnaires and to analize its relationship with asthma control. ⋯ The following authors have nothing to disclose: Caroline Becker, Carlos martinez Rivera, Jorge Abad Capa, Maria Luisa Martinez Ortiz, Marisa Rivera Ortún, Zoran Stojanovic, Laura Rodriguez Pons, Nuria Bruguera Avila, Joan RuizNo Product/Research Disclosure Information.